Next Article in Journal
Bulinus senegalensis and Bulinus umbilicatus Snail Infestations by the Schistosoma haematobium Group in Niakhar, Senegal
Previous Article in Journal / Special Issue
From Jekyll to Hyde: The Yeast–Hyphal Transition of Candida albicans
Article

Sphingolipid Inhibitors as an Alternative to Treat Candidiasis Caused by Fluconazole-Resistant Strains

1
Laboratório de Química Biológica de Microrganismos, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil
2
Laboratório de Bioquímica Microbiana, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil
3
Departamento de Medicina, División Ciencias de la Salud, Universidad del Norte, Km 5, vía Puerto Colombia, Área Metropolitana de Barranquilla 081007, Colombia
*
Author to whom correspondence should be addressed.
These authors contributed equally to the study.
Academic Editor: Jonathan Richardson
Pathogens 2021, 10(7), 856; https://doi.org/10.3390/pathogens10070856
Received: 9 June 2021 / Revised: 1 July 2021 / Accepted: 3 July 2021 / Published: 7 July 2021
(This article belongs to the Special Issue Candida albicans: A Major Fungal Pathogen of Humans)
Candida species are fungal pathogens known to cause a wide spectrum of diseases, and Candida albicans and Candida glabrata are the most common associated with invasive infections. A concerning aspect of invasive candidiasis is the emergence of resistant isolates, especially those highly resistant to fluconazole, the first choice of treatment for these infections. Fungal sphingolipids have been considered a potential target for new therapeutic approaches and some inhibitors have already been tested against pathogenic fungi. The present study therefore aimed to evaluate the action of two sphingolipid synthesis inhibitors, aureobasidin A and myriocin, against different C. albicans and C. glabrata strains, including clinical isolates resistant to fluconazole. Susceptibility tests of aureobasidin A and myriocin were performed using CLSI protocols, and their interaction with fluconazole was evaluated by a checkerboard protocol. All Candida strains tested were sensitive to both inhibitors. Regarding the evaluation of drug interaction, both aureobasidin A and myriocin were synergic with fluconazole, demonstrating that sphingolipid synthesis inhibition could enhance the effect of fluconazole. Thus, these results suggest that sphingolipid inhibitors in conjunction with fluconazole could be useful for treating candidiasis cases, especially those caused by fluconazole resistant isolates. View Full-Text
Keywords: Candida; sphingolipids; myriocin; fungal infections Candida; sphingolipids; myriocin; fungal infections
Show Figures

Graphical abstract

MDPI and ACS Style

Rollin-Pinheiro, R.; Bayona-Pacheco, B.; Domingos, L.T.S.; da Rocha Curvelo, J.A.; de Castro, G.M.M.; Barreto-Bergter, E.; Ferreira-Pereira, A. Sphingolipid Inhibitors as an Alternative to Treat Candidiasis Caused by Fluconazole-Resistant Strains. Pathogens 2021, 10, 856. https://doi.org/10.3390/pathogens10070856

AMA Style

Rollin-Pinheiro R, Bayona-Pacheco B, Domingos LTS, da Rocha Curvelo JA, de Castro GMM, Barreto-Bergter E, Ferreira-Pereira A. Sphingolipid Inhibitors as an Alternative to Treat Candidiasis Caused by Fluconazole-Resistant Strains. Pathogens. 2021; 10(7):856. https://doi.org/10.3390/pathogens10070856

Chicago/Turabian Style

Rollin-Pinheiro, Rodrigo, Brayan Bayona-Pacheco, Levy T.S. Domingos, Jose A. da Rocha Curvelo, Gabriellen M.M. de Castro, Eliana Barreto-Bergter, and Antonio Ferreira-Pereira. 2021. "Sphingolipid Inhibitors as an Alternative to Treat Candidiasis Caused by Fluconazole-Resistant Strains" Pathogens 10, no. 7: 856. https://doi.org/10.3390/pathogens10070856

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop